anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, medicinal virology. SUBSTANCE: immunization is carried out with vaccine containing at least two strains of influenza virus type B and/or each of influenza virus subtype A. Vaccine concentration is at the range from 2.7-4.2 mcg/0.5 ml to 2.7-4.2 ng/0.5 ml hemagglutinin for inactivated vaccine and from 3 x 4.5 lg ID 50 /0.2 ml - 3 x 6.5 lg ID 50 /0.2 ml to 3 x 3.5 lg ID 50 /0.2 ml - 3 x 5.5 lg ID 50 /0.2 ml for live antiinfluenza vaccine. Immunization requires the corresponding vaccine involving polyvalent preparation with that strain composition. EFFECT: enhanced effectiveness and safety of vaccine prophylaxis. 2 cl, 9 tbl
A massage bathing maintenance system suitable for a massage bathing equipment is provided. The system comprises at least one attached device, at least one slave control device, a master control device, and an analyzing unit. The at least one attached device is configured to actuate with regard to the massage bathing equipment. The at least one slave control device comprises a control unit configured to generate and transmit at least one actuating message according to at least one actuating-status of the at least one attached device. The master control device comprise a log-collecting unit configured to record the at least one actuating message of the at least one slave control device into a logs table. The analyzing unit is configured to analyze the at least one actuating message of the logs table so as to determine whether the actuation of at least one attached device is abnormal.
The invention discloses lactoferrin active peptide and application thereof. In a first aspect of the present application, a lactoferrin active peptide is provided, an amino acid sequence of the lactoferrin active peptide is any one of SEQ ID nos. 1 to 3, or an amino acid sequence obtained by modifying, substituting, deleting or adding at least one amino acid to an amino acid sequence represented by any one of SEQ ID nos. 1 to 3. The lactoferrin active peptide according to the embodiment of the application has at least the following beneficial effects: the lactoferrin active peptide with good stability and anticancer activity is discovered in the embodiment of the application through the separation, characterization and stability identification of lactoferrin digested by protease and the study on cancer cell specificity and cytotoxicity. Compared with full-length lactoferrin (flHLF), the lactoferrin active peptides have obviously improved anti-cancer activity on human cancer cell lines.
Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
OBJECTIVE: Functional polymorphisms of interleukin 16 (IL16) have been reported to be closely related to the risk of osteoarthritis (OA). However, how IL16 affects OA remains unclear. In this study, the role of IL16 in OA and the possible mechanisms were examined.
METHODS: We established a meniscal/ligament injury (MLI) post-traumatic OA model in Sprague Dawley rats and an IL1β-induced ADTC5 cells OA model. We detected the expression of IL16, novel-miR-81, MMP3, and MMP13 by quantitative real-time polymerase chain reaction. Western blot was performed to detect the expression of IL16, MMP3, and MMP13. The association between IL16 and novel-miR-81 was confirmed by luciferase reporter assay. Hematoxylin and eosin staining, Safranin O and Fast Green staining, and immunohistochemical staining were performed to clarify the effect of intra-articular injection of novel-miR-81 agomir in rats OA model.
RESULTS: IL16 was upregulated in OA model. Knockdown of IL16 and overexpression of novel-miR-81 downregulated the expression of MMP3 and MMP13. Importantly, IL16 was a key target of novel-miR-81. Intra-articular injection of novel-miR-81 agomir could attenuate OA progression in rats OA model.
CONCLUSION: Novel-miR-81 targeted IL16 to relieve OA, suggesting that novel-miR-81and IL16 may be new therapeutic targets for OA.
<P>PROBLEM TO BE SOLVED: To realize quantitatively producing a lyophilized reagent despite using a method simpler than ever.  <P>SOLUTION: The method for producing the lyophilized reagent comprises the following process: a chemical reagent solution is fed into a through-hole by making use of capillary force using a supporting member having the through-hole with holding ability to hold the reagent solution. With the reagent solution held in the through-hole, the reagent solution is e.g. brought into contact with an ultra-low-temperature cryogenic medium to freeze it in the through-hole. The thus frozen reagent is then ejected from the through-hole and lyophilized.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Background. The burden of sepsis is increasing worldwide. It is the cause of 8 million global deaths each year. Currently, treatment options are limited to antimicrobials and supportive care such as intravenous fluids, vasopressors, mechanical ventilation, and renal replacement therapy. In the absence of effective therapies specifically targeting the dysregulated immune response, prolonged use of these life-sustaining therapies can be debilitating. A growing body of evidence suggesting that vitamin C, an inexpensive and readily available intervention, is potentially lifesaving in sepsis. Intravenous vitamin C may be the first therapy to mitigate the dysregulated cascade of events that leads to sepsis. If proven effective, vitamin C could be used worldwide and drastically change outcomes in high- and low-income settings alike.

Objectives. To determine whether intravenous vitamin C, compared to placebo, reduces mortality and morbidity in sepsis (induced by bacterial and viral pathogens (as COVID-19)), and compare clinical and biochemical measures of organ dysfunction, and health-related quality of life (HRQoL) at 6 months. To ascertain the volume of distribution, clearance, and plasma concentration over a course of 96 hours of intravenous vitamin C 50 mg/kg of weight every 6 hours or matching placebo (pharmacokinetic (PK) substudy).

Methods. Patients will be randomly assigned to vitamin C (intravenous, 50 mg/kg every 6h) or placebo (0.9% NaCl or dextrose 5% in water) for 96 hours. Study personnel at the clinical sites will document the composite of death or persistent organ dysfunction at day 28. Daily assessments will occur for organ function, on days 1, 3, 7 for inflammation, infection, and endothelial injury biomarkers, at baseline for vitamin C level, and at 6 months for mortality and HRQoL. The LOVIT Trial will be conducted in adult general Canadian and international intensive care units. For the PK substudy: Blood samples will be drawn around the 8th dose at time 0 and then after administration at times 1h, 2h, 4h and 6h (the 6h level will be immediately prior to the next dose). The PK substudy will be conducted with 100 participants in 3 of the 25 participating centers.

Relevance. In the context of increasing off-label use of vitamin C for sepsis and ongoing trials of vitamin C bundled with other pharmacological interventions, the LOVIT Trial will constitute a rigorous assessment of the effect of vitamin C monotherapy on patient-important outcomes.
Tourette syndrome (TS) is a neurodevelopmental disorder with childhood onset characterized by the presence of chronic motor and vocal (phonic) tics. Tics typically begin between the ages of 4 - 7 years, frequently persist, and often lead to psychosocial, physical, functional, and academic difficulties. Epidemiological studies have shown that about 20-30% of children exhibit tics in a classroom setting whereas the estimated prevalence of impairing cases of TS is 1/100 - 1/1000 individuals. There is no cure for tics and a variety of behavioral and pharmacotherapies have been used successfully to suppress tics. Comprehensive Behavioral Intervention for Tics (CBIT) has been shown to be beneficial in several large trials as has habit reversal training (HRT), one of its major components. In the past, it has been suggested that only "competent and trained practitioners should administer CBIT." This proposal challenges that concept and believes that one can establish a successful front-line home-based CBIT treatment program that would be beneficial for the treatment of patients with tic symptoms throughout the country.

CBIT is a safe, effective, front-line treatment for TS. Nevertheless, the investigators emphasize the acute shortage of appropriately trained clinicians available to assist affected individuals. Hence, in this proposal the investigators will assess the effectiveness of a behavioral home-based, parent administered treatment by investigating at Johns Hopkins Hospital whether the home-based digital video disc (DVD) reduces tic severity comparable to that achieved with face-to-face treatment administered by an experienced therapist. The investigators' confidence in the success of this project is based on prior experiences with another childhood movement disorder, primary complex motor stereotypies. The potential significance of this project is enormous, recognizing that home-based therapy reduces health care costs, visits to practitioners, the need to train large numbers of therapists, and most importantly provides direct, available care for a greater number individuals affected with tics.
Pre-eclampsia remains a major cause of morbidity and mortality in pregnant women, as well in their newborns (1). Despite intense study, preeclampsia remains poorly understood and a major cause of maternal and foetal morbidity and mortality. It's clear that vascular endothelial dysfunction, which may lead to hypertension by imbalance between vasoactive, and vasodilator agents, is an important component of this disorder. The induction of endothelial dysfunction is probably multifactorial (2). Some researchers suggested that hereditary and acquired thrombophilia has been associated with recurrent pregnancy loss and gestational vascular complications, such as early-onset pre-eclampsia and placental abruption (3). Despite it is widely known that pregnancy induces a state of hypercoagulability (4), publications failed to demonstrate a uniform pattern of pathology that can carry the association between thrombophilia and adverse pregnancy outcomes, as between factor V Leiden mutation, MTHFR C677T mutation, G20210A Prothrombin gene mutation, Anti-thrombin III deficiency, Protein C,S deficiency and other causes of thrombophilia, different researchers claimed different causes of the previously mentioned as the one responsible for maternal thrombophilia (2, 3, 5). Others claimed racial variations were associated with the state of thrombophilia (6).

Other than standard routine and specific tests, various other methods are used to record coagulation profile. One of them is estimation by sonoclot, which is a viscoelastic hemostatic assays device (7). Sonoclot have practical advantages as point-of-care device for monitoring major hemorrhage including a set of parameters that assesses a global coagulation profile and can indicate the presence of hypercoagulable state (8). Establishing correlations between Sonoclot parameters and conventional hemostasis assays could open a path of better monitoring of patients with suspected coagulopathies, and can be helpful in guiding management of preeclampsia and preventing severe maternal outcomes (7).
Polyploidy occurs across the tree of life and is especially common in plants. Because newly formed cytotypes are often incompatible with their progenitors, polyploidy is also said to trigger "instantaneous" speciation. If a polyploid can self-fertilize or reproduce asexually, it is even possible for one individual to produce an entirely new lineage, but how often this scenario occurs is unclear. Here, we investigate the evolutionary history of the wild allotetraploid Mimulus sookensis, which was formed through hybridization between self-compatible, diploid species in the Mimulus guttatus complex. We generate a chromosome-scale reference assembly for M. sookensis and define its distinct subgenomes. Despite previous reports suggesting multiple origins of this highly selfing polyploid, we discover patterns of population genomic variation that provide unambiguous support for a single origin. One M. sookensis subgenome is clearly derived from the selfer Mimulus nasutus, which organellar variation suggests is the maternal progenitor. The ancestor of the other subgenome is less certain, but it shares variation with both Mimulus decorus and M. guttatus, two outcrossing diploids with geographic ranges that overlap broadly with M. sookensis. This study establishes M. sookensis as an example of instantaneous speciation, likely facilitated by the polyploid's predisposition to self-fertilize.
PCT No. PCT/US97/04024 Sec. 371 Date Aug. 19, 1998 Sec. 102(e) Date Aug. 19, 1998 PCT Filed Mar. 14, 1997 PCT Pub. No. WO97/33531 PCT Pub. Date Sep. 18, 1997Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by virtue of an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition includes an absorption enhancer and a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.
The invention provides application of pyrroloquinoline quinone in preparation of a medicine for improving diabetic nephropathy. In-vitro and in-vivo experiments show that PQQ can inhibit renal fibrosis and improve renal function in a diabetes mouse model, and has a protective effect on HK-2 cells stimulated by high sugar concentration. PQQ can alleviate diabetic nephropathy by inhibiting NF-. kappa.B/NLRP 3 inflammasome-mediated activation of the apoptosis pathway. These in vivo and in vitro findings provide the basis for the study of PQQ in the treatment of diabetes-related renal disease, demonstrating that PQQ supplementation can improve the development of DN. The application of PQQ in the aspects of health functional food and drug development and the like is widened, and a new idea is provided for the prevention and treatment of DN.
Purpose.Accurately visualizing and measuring blood flow is of utmost importance in maintaining optimal health and preventing the onset of various chronic diseases. One promising imaging technique that aids in visualizing perfusion in biological tissues is Multi-exposure Laser Speckle Contrast Imaging (MELSCI). MELSCI technique allows real-time quantitative measurements using multiple exposure times to obtain precise and reliable blood flow data. Additionally, the application of machine learning (ML) techniques can further enhance the accuracy of blood flow prediction in this imaging modality.Method.Our study focused on developing and evaluating Ensemble Learning ML techniques along with clustering algorithms for predicting blood flow rates in MELSCI. The effectiveness of these techniques was assessed using performance parameters, including accuracy, F1-score, precision, recall, specificity, and classification error rate.Result.Notably, the study revealed that Ensemble Learning with clustering emerged as the most accurate technique, achieving an impressive accuracy rate of 98.5%. Furthermore, it demonstrated a high recall of more than 91%, F1-score, the precision of more than 90%, higher specificity of 99%, and least classification error of 1.5%, highlighting its suitability and sustainability for flow prediction in MELSCI.Conclusion.The study's findings imply that Ensemble Learning can significantly contribute to enhancing the accuracy of blood flow prediction in MELSCI. This advancement holds substantial promise for healthcare professionals and researchers, as it facilitates improved understanding and assessment of perfusion within biological tissues, which will contribute to the maintenance of good health and prevention of chronic diseases.
Glaucoma and uveitis are non-vascular ocular diseases which are among the leading causes of blindness and visual loss. These conditions have distinct characteristics and mechanisms but share a multifactorial and complex nature, making their management challenging and burdensome for patients and clinicians. Furthermore, the lack of symptoms in the early stages of glaucoma and the diverse aetiology of uveitis hinder timely and accurate diagnoses, which are a cause of poor visual outcomes under both conditions. Although current treatment is effective in most cases, it is often associated with low patient adherence and adverse events, which directly impact the overall therapeutic success. Therefore, long-lasting alternatives with improved safety and efficacy are needed. Gene therapy, particularly utilising adeno-associated virus (AAV) vectors, has emerged as a promising approach to address unmet needs in these diseases. Engineered capsids with enhanced tropism and lower immunogenicity have been proposed, along with constructs designed for targeted and controlled expression. Additionally, several pathways implicated in the pathogenesis of these conditions have been targeted with single or multigene expression cassettes, gene editing and silencing approaches. This review discusses strategies employed in AAV-based gene therapies for glaucoma and non-infectious uveitis and provides an overview of current progress and future directions.
The invention discloses application of miRNA in liver cirrhosis diagnosis and treatment. miRNA is miRNA-548a-3p. By detecting the expression level of miRNA-548a-3p, miRNA-548a-3p can be used for diagnosing whether a patient has liver cirrhosis or is in the liver cirrhosis risk. As is shown in tests, the expression level of miRNA-548a-3p in a patient with liver cirrhosis is obviously lower than that of miRNA-548a-3p in a healthy person. On this basis, miRNA-548a-3p can also be used for preparing liver cirrhosis treatment medicine. Through miRNA-548a-3p, the sensitivity and specificity of liver cirrhosis diagnosis are greatly improved, and meanwhile a new target spot is provided for gene treatment of liver cirrhosis.
The study will be carried out between March 2021 and June 2021 in Istanbul University Istanbul Medical Faculty Pain Medicine Clinic. Patients who undergone erector spinae plane block for any indication over the age of 18 will be included in the study.

All procedures will be performed in the operating room under standard monitorization (ECG, pulse oximetry, non-invasive blood pressure) and all patients will be in the prone position. The application area will be sterilized with povidone-iodine solution. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The target area will be visualized by General Electrics (GE) Logiq e Ultrasound device using a 10-12 MHz linear probe or 1-4 MHz curvilinear probe. Transverse processes and erector spina muscles will be visualised at the target vertebral level. After local anesthesia (1-2 cc 2% lidocaine), a 20 gauge spinal needle will be inserted using the "in-plane technique". The needle will be advanced to the transverse process, after it's position is confirmed with hydrodissection, a solution of 40 mg triamcinolone, 10 ml 0,5% bupivacaine, 10 ml radiopaque contrast agent will be injected. Contrast spread will be evaluated with the fluoroscopy in the anterior-posterior and lateral positions immediately and 30 minutes after the procedure. The level of contrast radiating in the AP plane and passing through the paravertebral space and the epidural distance in the lateral plane will be noted. In addition, sensory examination with a pin prick test will be performed to determine the presence of dermatomal hypoalgesia and/or analgesia.
BACKGROUND: 8-Oxoguanine DNA glycosylase (OGG1), a well-known DNA repair enzyme, has been demonstrated to promote lung fibrosis, while the specific regulatory mechanism of OGG1 during pulmonary fibrosis remains unclarified.
METHODS: A bleomycin (BLM)-induced mouse pulmonary fibrosis model was established, and TH5487 (the small molecule OGG1 inhibitor) and Mitochondrial division inhibitor 1 (Mdivi-1) were used for administration. Histopathological injury of the lung tissues was assessed. The profibrotic factors and oxidative stress-related factors were examined using the commercial kits. Western blot was used to examine protein expression and immunofluorescence analysis was conducted to assess macrophages polarization and autophagy. The conditional medium from M2 macrophages was harvested and added to HFL-1 cells for culture to simulate the immune microenvironment around fibroblasts during pulmonary fibrosis. Subsequently, the loss- and gain-of function experiments were conducted to further confirm the molecular mechanism of OGG1/PINK1.
RESULTS: In BLM-induced pulmonary fibrosis, OGG1 was upregulated while PINK1/Parkin was downregulated. Macrophages were activated and polarized to M2 phenotype. TH5487 administration effectively mitigated pulmonary fibrosis, M2 macrophage polarization, oxidative stress and mitochondrial dysfunction while promoted PINK1/Parkin-mediated mitophagy in lung tissues of BLM-induced mice, which was partly hindered by Mdivi-1. PINK1 overexpression restricted M2 macrophages-induced oxidative stress, mitochondrial dysfunction and mitophagy inactivation in lung fibroblast cells, and OGG1 knockdown could promote PINK1/Parkin expression and alleviate M2 macrophages-induced mitochondrial dysfunction in HFL-1 cells.
CONCLUSION: OGG1 inhibition protects against pulmonary fibrosis, which is partly via activating PINK1/Parkin-mediated mitophagy and retarding M2 macrophage polarization, providing a therapeutic target for pulmonary fibrosis.
The new agent contains Royal jelly, chestnut flour corn oil and stinging nettles. The agent pref. contains 1.5% Royal jelly 18.5% chestnut flour and 79.0% stinging nettles. USE/ADVANTAGE - The agent is used to retard the aging process. Royal jelly promotes and strengthens cell growth and chestnut flour maintains skin elasticity by keeping in moisture. Corn oil is rich in vitamin E to protect the skin from damaging environmental influences and stinging nettles are blood cleaning ensuring that the other ingredients of the agent circulate in the blood in the outer skin layer
Three sequential non-inferiority tests are planned. First, three readers will review the original 2-mSv images. Second, the readers will review the 75%-dose images. After the readers review the 75%-dose images and before the readers reviewed the 50%-dose images, the non-inferiority of 75% dose to the original dose will be tested. If the non-inferiority is not accepted, the study will be terminated with the conclusion of 2 mSv as the lowest acceptable dose. If the non-inferiority is accepted, the study will be continue to the next step. In the same manner, the readers will review the next lower-dose images (50% and then 25%), and then the noninferiority will be tested against the original dose.